ONCT vs. LIPO, MTVA, NLSP, MYNZ, GTBP, HCWB, JAGX, ATNF, APLM, and FRTX
Should you be buying Oncternal Therapeutics stock or one of its competitors? The main competitors of Oncternal Therapeutics include Lipella Pharmaceuticals (LIPO), MetaVia (MTVA), NLS Pharmaceutics (NLSP), Mainz Biomed (MYNZ), GT Biopharma (GTBP), HCW Biologics (HCWB), Jaguar Health (JAGX), 180 Life Sciences (ATNF), Apollomics (APLM), and Fresh Tracks Therapeutics (FRTX). These companies are all part of the "pharmaceutical products" industry.
Oncternal Therapeutics vs.
Oncternal Therapeutics (NASDAQ:ONCT) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, community ranking, dividends and analyst recommendations.
16.0% of Oncternal Therapeutics shares are held by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are held by institutional investors. 11.2% of Oncternal Therapeutics shares are held by company insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, Oncternal Therapeutics had 2 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 3 mentions for Oncternal Therapeutics and 1 mentions for Lipella Pharmaceuticals. Oncternal Therapeutics' average media sentiment score of 0.00 beat Lipella Pharmaceuticals' score of -0.24 indicating that Oncternal Therapeutics is being referred to more favorably in the media.
Lipella Pharmaceuticals has lower revenue, but higher earnings than Oncternal Therapeutics. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than Oncternal Therapeutics, indicating that it is currently the more affordable of the two stocks.
Oncternal Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 1,798.97%. Given Oncternal Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Oncternal Therapeutics is more favorable than Lipella Pharmaceuticals.
Oncternal Therapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, Lipella Pharmaceuticals has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500.
Lipella Pharmaceuticals has a net margin of -882.82% compared to Oncternal Therapeutics' net margin of -1,599.95%. Oncternal Therapeutics' return on equity of -177.58% beat Lipella Pharmaceuticals' return on equity.
Oncternal Therapeutics received 31 more outperform votes than Lipella Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Lipella Pharmaceuticals an outperform vote while only 22.07% of users gave Oncternal Therapeutics an outperform vote.
Summary
Oncternal Therapeutics beats Lipella Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Oncternal Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncternal Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ONCT) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy ONCT Stock Free ONCT Stock Alerts